Shukra Pharmaceuticals (524632) Q3 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 24/25 earnings summary
6 Jun, 2025Executive summary
Board approved unaudited financial results for the quarter and nine months ended 31st December 2024, following audit committee review.
Appointed Mr. Jay Gandhi as Internal Auditor and Ms. Shilpa Shah as Secretarial Auditor for FY 2024-25.
Financial highlights
Revenue from operations for the quarter ended 31st Dec 2024 was ₹1,058.43 lakhs, up from ₹555.52 lakhs in the previous quarter.
Net profit for the quarter was ₹316.44 lakhs, compared to ₹53.89 lakhs in the previous quarter and ₹942.18 lakhs in the same quarter last year.
For the nine months ended 31st Dec 2024, revenue was ₹6,368.90 lakhs and net profit was ₹418.87 lakhs.
Basic and diluted EPS for the quarter were ₹0.72, compared to ₹0.12 in the previous quarter.
Outlook and guidance
Internal and secretarial audits for FY 2024-25 are expected to enhance compliance and internal controls.
Latest events from Shukra Pharmaceuticals
- Sales and exports surged, but higher depreciation cut profit as injectable expansion advanced.524632
Q4 96/97 - Sales grew 18%, profit rose, and injectable production was poised to begin amid operating cash outflow.524632Q4 97/98
- Sales and exports surged as expansion funding coincided with negative operating cash flow.524632Q4 99/00
- Turnover rose 22.72%; injection-plant launch awaited regulatory approval.524632Q4 98/99
- Higher sales, lower PAT after a ₹5.65m write-off, and restructuring define FY16.524632Q4 15/16
- Revenue surged, but profit collapsed amid qualified audit and compliance concerns.524632Q4 19/20
- Revenue and profit surged; net debt turned negative and a ₹1 dividend was proposed.524632Q4 23/24
- FY23 earnings surged as export growth advanced alongside higher receivables and tax exposure.524632Q4 22/23
- A bank settlement lifted FY12 profit despite declining revenue and restructuring pressures.524632Q4 11/12
- Revenue declined, losses deepened, and restructuring remained central to the outlook.524632Q4 12/13